Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 54 clinical trials
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study (TRUST)

). Half of the participants will receive immediate cellular therapy followed by sham therapy 6 months later, while the other half will receive immediate sham therapy followed by cellular therapy 6 months

stem cell therapy
venous obstruction
sham therapy
  • 11 Feb, 2022
  • 1 location
RAFT - Clinical Trial of RAFT for Aniridia Related Keratopathy

The RAFT trial is a first in human trial of a novel cellular therapy called RAFT-OS (Real Architecture for 3D Tissues Ocular Surface) developed and manufactured by Cells for Sight Stem Cell

  • 20 Dec, 2021
  • 1 location
Infusion of Donor Derived Cytokine Induced Killer (CIK) Cells in Hematological Patients Relapsed After Haploidentical Stem Cell Transplant

The haematological neoplasia relapse is the cause of higher mortality after allogeneic stem cell transplantation (HSCT). When transplantation fails the most common therapeutic strategy is to increase the antitumor activity of the donor's immune system through the infusion of donor Lymphocytes (DLI). The use of DLI may limit the relapse, …

  • 01 Jan, 2022
  • 1 location
Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma

This Research study is being done to characterize the safety, tolerability, and preliminary antitumor activity of the NEXI-002 T cell product (a new experimental therapy), which contains populations of CD8+ T cells targeting multiple Myeloma associated antigen peptides in patients with relapsed refractory multiple myeloma (MM). The study will enroll …

  • 27 Jan, 2021
  • 4 locations
Patient Reported Outcomes and Patient Education in Cellular Therapy Patients

The purpose of this research is to provide an educational visit addressing common emotional stressors involved in the transplant/CAR-T process, and determine if this added education improves levels of anxiety, depression, and fatigue after transplant/CART in comparison to people who do not receive the brief educational visit.

  • 01 May, 2021
  • 1 location
Cellular Therapy for Type 1 Diabetes Using Mesenchymal Stem Cells

The goal of this study is to determine the safety and efficacy of fresh metabolically active allogeneic umbilical cord-derived mesenchymal stromal cells (UC-MSCs) for the treatment of new-onset type 1 diabetes (T1D) and to understand the mechanisms of protection. If proven effective, such a strategy can be used as a …

autoimmune disease
  • 26 Apr, 2022
  • 1 location
Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (ACTION)

It is believed that the body's immune system protects the body by attacking and killing tumor cells. T-lymphocytes (T-cells) are part of the immune system and can attack when they recognize special proteins on the surface of tumors. In most patients with advanced cancer, T-cells are not stimulated enough to …

karnofsky performance status
malignant glioma
neutrophil count
  • 12 May, 2022
  • 3 locations
PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy (PEACH)

A Phase I open-label, multicenter study, to evaluate the safety, feasibility, and maximum tolerated dose (MTD) of treating children with newly diagnosed DIPG or recurrent neuroblastoma with molecular targeted therapy in combination with adoptive cell therapy (Total tumor mRNA-pulsed autologous Dendritic Cells (DCs) (TTRNA-DCs), Tumor-specific ex vivo expanded autologous lymphocyte …

granulocyte colony stimulating factor
bone marrow procedure
colony stimulating factor
  • 14 May, 2022
  • 2 locations
Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer

Cytokine-induced killer (CIK) cells show cytolytic activity against tumor. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining Radiation therapy with adoptive cellular

esophageal cancer
esophagus cancer
esophageal carcinoma
  • 23 Jan, 2021
  • 1 location
PRGN-3006 Adoptive Cellular Therapy for Relapsed or Refractory AML or High Risk MDS

This is a first-in-human dose escalation/dose expansion study to evaluate safety and identify best dose (or recommended Phase 2 dose) of modified immune cells, PRGN-3006 (autologous chimeric antigen receptor (CAR) T cells), in adult patients with relapsed or recurred acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic …

serum bilirubin level
bone marrow procedure
ejection fraction
myeloid leukemia
  • 07 Feb, 2022
  • 1 location